Effects of Coenzyme Q10 in PSP and CBD

Lahey Health

Status and phase

Completed

Phase 3

Phase 2

Conditions

Neurological Disorders

Progressive Supranuclear Palsy

Treatments

Drug: CoQ10

Study type

Interventional

Funder types

Other

Identifiers

NCT00532571

CoQ10 with PSP/CBD

Details and patient eligibility

About

To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who were diagnosed within the past 5 years
Age > 40
Subjects receiving anticholinergics, amantadine, dopamine agonists, carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 days prior to baseline visit.
Patients agreeable to participate in the study.

Exclusion criteria

Prior or concurrent therapy with anticholinergics, amantadine,a dopamine agonist,carbidopa/levodopa or comtan within 30 days of the baseline visit.
Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs.
History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant.
Previous use of coenzyme Q10 within 60 days of the baseline visit.